|Bid||8,689.00 x 0|
|Ask||8,691.00 x 0|
|Day's range||8,667.00 - 8,768.55|
|52-week range||6,499.80 - 9,081.00|
|Beta (5Y monthly)||0.18|
|PE ratio (TTM)||41.56|
|Earnings date||12 Nov 2021|
|Forward dividend & yield||2.02 (2.30%)|
|Ex-dividend date||12 Aug 2021|
|1y target est||95.81|
In this Motley Fool Live video recorded on Oct. 6, Motley Fool contributors Keith Speights and Brian Orelli discuss how big the market opportunity might be for AstraZeneca's COVID-19 therapy. Keith Speights: On Tuesday, AstraZeneca filed for Emergency Use Authorization for its COVID-19 antibody therapy.
Dr. Francis Collins, Outgoing NIH Director, joins Yahoo Finance’s Anjalee Khemlani to discuss Covid-19 vaccine production, drug development research, and misinformation surrounding Covid-19 vaccines.